Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAmbetter Georgia RELiZORB Coverage & Prior Auth | …
    Ask Trek AI about this page
    CurrentAmbetter GeorgiaPolicy CP.MP.252

    Immobilized Lipase Cartridges (RELiZORB)

    Customize your policy alerts

    Sign up for Ambetter Georgia Policy CP.MP.252 alerts

    Get alerted when Policy CP.MP.252 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria for use of RELiZORB immobilized lipase cartridges with enteral feeding for members of Ambetter Georgia / Centene-affiliated health plans.

    Policy Summary
    PayerAmbetter Georgia
    PolicyImmobilized Lipase Cartridges (RELiZORB)
    Policy CodePolicy CP.MP.252
    Change TypeNo material change
    Effective DateAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and provide documentation showing enteral feeding requirement, confirmed EPI by fecal elastase, PERT optimization or contraindication, and requested daily cartridge quantity within policy limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 2max cartridges/day ≤6 months
    Up to 6max cartridges/day >6 months
    B4105billing code
    Fecal elastaserequired test

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medical Necessity and Coverage Criteria

    Initial therapy / Medical necessity criteria

    Covered when ALL of the following are met:

    Main criteria

    • Enteral feeding requirement and PERT status

      • Member/enrollee requires enteral feeding AND documented failure to achieve or maintain enteral nutrition goals despite optimization of oral pancreatic enzyme replacement therapy (PERT) and nutritional support
      • Member/enrollee requires enteral feeding AND documented contraindication to or intolerance of oral PERT during enteral feeding
    • Established diagnosis of exocrine pancreatic insufficiency (EPI) confirmed by fecal elastase
    • Allowed daily cartridge request

      • Request is for up to two cartridges per day for member/enrollees ≤ six months of age
      • Request is for up to six cartridges per day for member/enrollees > six months of age

    Requests that exceed the specified daily cartridge limits are outside the coverage criteria. Specifically, the policy allows up to 2 cartridges per day for members ≤ 6 months of age and up to 6 cartridges per day for members > 6 months of age. Requests for quantities greater than these limits may be denied as not meeting the policy’s allowable cartridge thresholds.

    RELiZORB use is covered only when the member has confirmed exocrine pancreatic insufficiency (EPI) by fecal elastase and one of the following applies: the member requires enteral feeding and has either (1) documented failure to achieve or maintain enteral nutrition goals despite optimization of oral pancreatic enzyme replacement therapy (PERT) and nutritional support, or (2) a documented contraindication to or intolerance of oral PERT during enteral feeding. Use of RELiZORB when these conditions are not met (no confirmed EPI, PERT not attempted/optimized without documented contraindication or intolerance, or requested quantities exceeding policy limits) would not meet medical necessity.

    Coding and Quantity Limits

    Referenced HCPCSHCPCS
    B4105In-line cartridge containing digestive enzyme(s) for enteral feeding, each
    Maximum cartridges per day — age-based limits
    Age-based maximum cartridges per day (≤6 months)Up to 2 cartridges per day for members/enrollees ≤ six months of age.
    Age-based maximum cartridges per day (>6 months)Up to 6 cartridges per day for members/enrollees > six months of age.
    Context for limitsRequests exceeding these specified daily cartridge limits are outside the coverage criteria and may be denied.

    Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization required; medical necessity must be met

    Prior authorization is required for requests for immobilized lipase cartridges (RELiZORB). All requests must meet the policy's medical necessity criteria and include supporting documentation as specified in the policy.

    Step Therapy

    Attempt and optimize oral PERT prior to approval

    The member must have attempted and had optimization of oral pancreatic enzyme replacement therapy (PERT) before RELiZORB will be approved, unless there is a documented contraindication or intolerance to oral PERT during enteral feeding.

    Documentation Required

    Documentation and coding required (including B4105)

    Submit documentation showing the member requires enteral feeding, an established diagnosis of EPI confirmed by fecal elastase, evidence of failure to achieve or maintain enteral nutrition goals despite optimized oral PERT (or documented contraindication/intolerance), and the requested daily cartridge quantity within policy limits. Use HCPCS code B4105 to bill the in-line cartridge.

    • Evidence of enteral feeding.
    • Fecal elastase result confirming EPI.
    • Clinical notes documenting failure to meet/maintain enteral nutrition goals despite optimized oral PERT, or documentation of contraindication/intolerance to oral PERT.
    • Requested number of cartridges per day consistent with limits (≤2/day for ≤6 months; ≤6/day for >6 months).
    • Billing code: B4105 (In-line cartridge containing digestive enzyme(s) for enteral feeding, each).
    Denial Risk

    Denial triggers — missing criteria or exceeding limits

    Requests that fail to meet every element of the medical necessity criteria may be denied. Common denial triggers include lack of enteral feeding, absence of confirmed EPI by fecal elastase, no documented trial/optimization of oral PERT (or no documented contraindication/intolerance), or requests exceeding the allowed daily cartridge limits.

    • No documentation that the member requires enteral feeding.
    • No fecal elastase confirming EPI.
    • No record of attempted/optimized oral PERT and no documented contraindication/intolerance.
    • Requested cartridges exceed limits (more than 2/day for members ≤6 months; more than 6/day for members >6 months).

    Background

    RELiZORB is an FDA‑cleared single‑use in‑line immobilized lipase cartridge intended for use with enteral feeding systems to hydrolyze triglycerides in enteral formulas and improve fat absorption for individuals with exocrine pancreatic insufficiency (EPI). It is intended for members who require enteral feeding and continue to have fat malabsorption despite optimized oral PERT or who cannot tolerate or have contraindications to oral PERT.

    Definitions

    RELiZORB — immobilized lipase cartridge (key facts)
    Device descriptionRELiZORB is an FDA‑cleared, single‑use in‑line immobilized lipase cartridge used with enteral feeding systems to hydrolyze triglycerides in enteral formulas into absorbable fatty acids and monoglycerides before entering the gastrointestinal tract.
    FunctionContains immobilized lipase that hydrolyzes fats in formula to mimic pancreatic lipase release and enhance fat absorption and utilization for individuals with insufficient pancreatic lipase.
    Intended use populationDesigned to support individuals with exocrine pancreatic insufficiency or related conditions who receive enteral nutrition and have ongoing fat malabsorption despite standard therapy.
    Exocrine pancreatic insufficiency (EPI) — definition and clinical implications
    DefinitionExocrine pancreatic insufficiency (EPI) is a disorder caused by failure of the pancreas to deliver a minimum threshold level of pancreatic digestive enzymes to the intestine, leading to maldigestion and malabsorption of nutrients.
    Clinical consequencesEPI can cause maldigestion and malabsorption of macronutrients, decreased caloric absorption, impaired utilization of essential fatty acids, and deficiencies of fat‑soluble vitamins (A, D, E, K), with adverse effects on nutritional status and quality of life.
    Relation to enteral feeding and PERTStandard of care is pancreatic enzyme replacement therapy (PERT); however, some individuals receiving enteral nutrition continue to have fat malabsorption despite appropriate PERT and may benefit from RELiZORB.
    Policy Summary
    PayerAmbetter Georgia
    PolicyImmobilized Lipase Cartridges (RELiZORB)
    Policy CodePolicy CP.MP.252
    Change TypeNo material change
    Effective DateAug 1, 2026
    Next Review Date
    Key ActionObtain prior authorization and provide documentation showing enteral feeding requirement, confirmed EPI by fecal elastase, PERT optimization or contraindication, and requested daily cartridge quantity within policy limits.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Quantity LimitsAuthorization, Documentation, and Provider RequirementsBackgroundDefinitions